Cargando…

Formulation Composition and Process Affect Counterion for CSP7 Peptide

Counterions commonly remain with peptides in salt form after peptide purification. In animal and human studies, acetate counterions are a safer and more acceptable choice for peptides than others (e.g., trifluoroacetate counterions). Various salt forms of caveolin-1 scaffolding domain (CSP7) affect...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahakijpijarn, Sawittree, Moon, Chaeho, Koleng, John J., Williams, Robert O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835953/
https://www.ncbi.nlm.nih.gov/pubmed/31569515
http://dx.doi.org/10.3390/pharmaceutics11100498
_version_ 1783466794851237888
author Sahakijpijarn, Sawittree
Moon, Chaeho
Koleng, John J.
Williams, Robert O.
author_facet Sahakijpijarn, Sawittree
Moon, Chaeho
Koleng, John J.
Williams, Robert O.
author_sort Sahakijpijarn, Sawittree
collection PubMed
description Counterions commonly remain with peptides in salt form after peptide purification. In animal and human studies, acetate counterions are a safer and more acceptable choice for peptides than others (e.g., trifluoroacetate counterions). Various salt forms of caveolin-1 scaffolding domain (CSP7) affect counterion volatilization. The development of lyophilized formulations containing volatile compounds is a challenge because these compounds sublimate away during the process. This work aims to investigate the effect of excipients and lyophilization parameters on the preservation of volatile compounds after lyophilization. The peak areas obtained from (1)H and (19)F NMR spectra were used to calculate the molar ratio of counterions to CSP7. We found that the pH modifier excipient had the greatest impact on the loss of counterions. By optimizing the molar ratio of bulking agent to CSP7, volatile compounds can be preserved after lyophilization. Higher chamber pressure during lyophilization can lower the sublimation rate of volatile compounds. Moreover, the loss of volatile compounds affects the stability of CSP7 due to the pH shift of reconstituted solutions, thereby causing peptide aggregation. The optimization of the formulation and processing helps preserve volatile compounds, thus minimizing the pH change of reconstituted solutions and maintaining the stability of peptide.
format Online
Article
Text
id pubmed-6835953
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68359532019-11-25 Formulation Composition and Process Affect Counterion for CSP7 Peptide Sahakijpijarn, Sawittree Moon, Chaeho Koleng, John J. Williams, Robert O. Pharmaceutics Article Counterions commonly remain with peptides in salt form after peptide purification. In animal and human studies, acetate counterions are a safer and more acceptable choice for peptides than others (e.g., trifluoroacetate counterions). Various salt forms of caveolin-1 scaffolding domain (CSP7) affect counterion volatilization. The development of lyophilized formulations containing volatile compounds is a challenge because these compounds sublimate away during the process. This work aims to investigate the effect of excipients and lyophilization parameters on the preservation of volatile compounds after lyophilization. The peak areas obtained from (1)H and (19)F NMR spectra were used to calculate the molar ratio of counterions to CSP7. We found that the pH modifier excipient had the greatest impact on the loss of counterions. By optimizing the molar ratio of bulking agent to CSP7, volatile compounds can be preserved after lyophilization. Higher chamber pressure during lyophilization can lower the sublimation rate of volatile compounds. Moreover, the loss of volatile compounds affects the stability of CSP7 due to the pH shift of reconstituted solutions, thereby causing peptide aggregation. The optimization of the formulation and processing helps preserve volatile compounds, thus minimizing the pH change of reconstituted solutions and maintaining the stability of peptide. MDPI 2019-09-29 /pmc/articles/PMC6835953/ /pubmed/31569515 http://dx.doi.org/10.3390/pharmaceutics11100498 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sahakijpijarn, Sawittree
Moon, Chaeho
Koleng, John J.
Williams, Robert O.
Formulation Composition and Process Affect Counterion for CSP7 Peptide
title Formulation Composition and Process Affect Counterion for CSP7 Peptide
title_full Formulation Composition and Process Affect Counterion for CSP7 Peptide
title_fullStr Formulation Composition and Process Affect Counterion for CSP7 Peptide
title_full_unstemmed Formulation Composition and Process Affect Counterion for CSP7 Peptide
title_short Formulation Composition and Process Affect Counterion for CSP7 Peptide
title_sort formulation composition and process affect counterion for csp7 peptide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835953/
https://www.ncbi.nlm.nih.gov/pubmed/31569515
http://dx.doi.org/10.3390/pharmaceutics11100498
work_keys_str_mv AT sahakijpijarnsawittree formulationcompositionandprocessaffectcounterionforcsp7peptide
AT moonchaeho formulationcompositionandprocessaffectcounterionforcsp7peptide
AT kolengjohnj formulationcompositionandprocessaffectcounterionforcsp7peptide
AT williamsroberto formulationcompositionandprocessaffectcounterionforcsp7peptide